

Agile Therapeutics Investor Relations Department 101 Poor Farm Road Princeton, NJ 08540 United States

Visit IR website ☐ Sign-up for email alerts ☐

| NASDAQ: AGRX  |                            |
|---------------|----------------------------|
| Last Trade:   | 3.80                       |
| Trade Time:   | 4:00 PM ET<br>Jun 26, 2017 |
| Change:       | 0.00 (0.000%)              |
| Day Range     | N/A - N/A                  |
| 52-Week Range | 1.82 - 8.15                |
| Volume        | N/A                        |
|               |                            |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability.

## **Stock Performance**



## Press Releases [View all]

May 8, 2017

<u>Agile Therapeutics Reports First Quarter</u> <u>2017 Financial Results</u>

May 6, 2017

Agile Therapeutics Reports Additional Phase
3 SECURE Study Results Relating to
Twirla® at ACOG 2017

May 3, 2017

Agile Therapeutics to Present Additional
Phase 3 Data at the 2017 Annual Clinical and
Scientific Meeting of the American Congress
of Obstetricians and Gynecologists

Apr 27, 2017

Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017
Congress on Women's Health

Apr 11, 2017

Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA

## Financials [View all]

Mar 15, 2017 Annual Report (10-K)

Apr 24, 2017
Proxy Statement (DEF 14A)

May 8, 2017 Quarterly Report (10-Q)

Nov 7, 2016 Quarterly Report (10-Q)

Aug 8, 2016 Quarterly Report (10-Q)